Atara Biotherapeutics is halving its head count as it navigates the fallout from the FDA’s move to halt trials of the allogeneic T-cell immunotherapy Ebvallo and a CAR-T candidate. Atara ...

Earnings Estimate Revisions for Atara Biotherapeutics This drug developer is expected to earn -$12.12 per share for the fiscal year ending December 2024, which represents a year-over-year change ...

Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO ™ BLA resubmission in the U.S. Atara remains focused on delivering on the future financial value ...

Atara Biotherapeutics Inc (ATRA) has disclosed a new risk, in the Corporate Activity and Growth category. See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze ...

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $1.19 per share versus the Zacks Consensus Estimate of a loss of $3.82. This compares to loss of $14 per share a year ago. These ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Atara Biotherapeutics has a beta of 0.49, meaning that its share price is 51% ...

In February, Atara Biotherapeutics paused enrolment into a trial of a CAR-T cell therapy for mesothelioma after a patient death. Now, its partner Bayer has backed out of a partnership covering two ...

Atara Biotherapeutics has become the first biotech to win regulatory approval for a T-cell therapy based on donated cells, rather than relying on cells harvested from patients and processed in a lab.

Atara announced on January 16, 2025, that it had received "a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the EBVALLOTM (tabelecleucel) Biologics License ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for ...